Clinical trials · Washington
Metastatic Pancreatic Adenocarcinoma clinical trials in Washington
We’re tracking 24 recruiting metastatic pancreatic adenocarcinoma studies with a site in Washington — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Washington
- NCT07562152RecruitingPhase 3
Atebimetinib Plus Gemcitabine/Nab-Paclitaxel for New Pancreatic Cancer
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
Seattle, WashingtonAges 18 years+ - NCT07645651RecruitingPhase 1
Samuraciclib for treatable basal pancreatic cancer
This trial tests a new drug called samuraciclib in people with a specific type of pancreatic cancer that can be removed with surgery or is confined to the pancreas. The drug may help stop the cancer from growing, and this study aims to see if it is safe and effective before surgery.
Seattle, WashingtonAges 18 years+ - NCT07491445RecruitingPhase 3
Daraxonrasib plus chemo for first-line metastatic pancreatic cancer
This trial tests a new targeted therapy (daraxonrasib) combined with standard chemotherapy as the first treatment for people whose pancreatic cancer has spread. The goal is to see if this combination can help shrink or control the cancer better than chemotherapy alone.
Seattle, WashingtonAges 18 years+ - NCT07409272RecruitingPhase 3
Study of setidegrasib with chemo for pancreatic cancer
This trial tests a new drug called setidegrasib, given with two types of chemotherapy (mFOLFIRINOX or NALIRIFOX), for people whose pancreatic cancer has spread and has a specific genetic change called KRAS G12D. The goal is to see if adding setidegrasib helps control the cancer better than chemo alone.
Seattle, WashingtonAges 18 years+ - NCT05254171RecruitingPhase 2/Phase 3
Trial adds SBP-101 to standard chemo for pancreatic cancer
This trial studies whether adding SBP-101 to standard chemotherapy (gemcitabine plus nab-paclitaxel) can improve outcomes in people with metastatic pancreatic cancer. You may be eligible if you have not yet started treatment for metastatic disease and meet other health and test requirements.
Tacoma, WashingtonAges 18 years+ - NCT05365581RecruitingPhase 1
Study drug for stomach and pancreatic cancers with lab-checked targets
This Phase 1 trial tests ASP2138 alone or with other cancer medicines in adults with stomach (including GEJ) or pancreatic cancer. You may be eligible if your tumor has a specific protein marker and your health tests and scan results meet safety requirements.
Seattle, WashingtonAges 18 years+ - NCT06445062RecruitingPhase 1/Phase 2
Study of new RAS inhibitors for GI solid tumors
This trial tests new drugs that target specific RAS mutations in advanced gastrointestinal cancers, like pancreatic or colorectal cancer. It aims to see if these drugs can shrink tumors or slow their growth.
Seattle, WashingtonAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Seattle, WashingtonAges 18 years+ - NCT06998940RecruitingPhase 3
Chemotherapy with or without panitumumab for pancreatic cancer
This trial tests whether adding a targeted drug called panitumumab to standard chemotherapy can help people with a certain type of pancreatic cancer that has spread. It is for patients whose tumors do not have a KRAS mutation and who have already had one line of chemotherapy.
Seattle, WashingtonAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Seattle, WashingtonAges 18 years+ - NCT04858334RecruitingPhase 2
Olaparib after pancreatic cancer surgery for BRCA or PALB2 mutations
This trial studies whether olaparib (a targeted cancer medicine) can help prevent pancreatic cancer from coming back after surgery in people with BRCA1, BRCA2, or PALB2 mutations. You would get olaparib or a placebo (inactive pill) and be closely followed to see if recurrence is reduced.
Aberdeen, WashingtonAges 18 years+ - NCT07522073RecruitingPhase 3
Chemotherapy with or without KRAS inhibitor for pancreatic cancer
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
Olympia, WashingtonAges 18 years+ - NCT06989437RecruitingPhase 2/Phase 3
Study of Ponsegromab for Pancreatic Cancer with Weight Loss
This study tests an experimental drug called ponsegromab for people with advanced pancreatic cancer who experience severe weight loss and fatigue. It aims to see if the drug can help improve weight and energy levels while you continue standard chemotherapy.
Seattle, WashingtonAges 18 years+ - NCT07644559RecruitingPhase 2
VS-7375 for KRAS G12D pancreatic cancer
This study tests a new drug called VS-7375, combined with cetuximab, for pancreatic cancer patients whose tumors have a specific genetic mutation called KRAS G12D. The goal is to see if this combination can shrink tumors and help patients live longer.
Seattle, WashingtonAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Tacoma, WashingtonAges 18 years+ - NCT06562192RecruitingPhase 1
Testing a radioactive drug for advanced pancreatic, lung, breast, and colorectal cancers
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
Seattle, WashingtonAges 18–100 - NCT05245500RecruitingPhase 1
Study drug for solid tumors with MTAP gene deletion
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
Seattle, WashingtonAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Seattle, WashingtonAges 1–30 - NCT06586515RecruitingPhase 1
Testing a new drug for cancers with KRAS G12D mutation
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
Seattle, WashingtonAges 18 years+ - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for KRAS G12D solid tumors
This trial tests a new oral drug called VS-7375 for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if it can shrink tumors or slow their growth.
Seattle, WashingtonAges 18 years+ - NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Seattle, WashingtonAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Seattle, WashingtonAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Seattle, WashingtonAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Aberdeen, WashingtonAges 18 years+
Metastatic Pancreatic Adenocarcinoma trials by city in Washington
Where these studies are running in Washington
Institutions with a site for the recruiting metastatic pancreatic adenocarcinoma studies listed above.
- Fred Hutchinson Cancer Center · 10 studies
- Virginia Mason Medical Center · 5 studies
- Swedish Cancer Institute-Edmonds · 4 studies
- Swedish Medical Center · 4 studies
- Kadlec Clinic Hematology and Oncology · 3 studies
- PeaceHealth Saint John Medical Center · 3 studies
- PeaceHealth Saint Joseph Medical Center · 3 studies
- PeaceHealth Southwest Medical Center · 3 studies
What taking part in a metastatic pancreatic adenocarcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Metastatic Pancreatic Adenocarcinoma trials in other states
Common questions
- Are there metastatic pancreatic adenocarcinoma clinical trials in Washington?
- Yes. We're currently tracking 24 recruiting metastatic pancreatic adenocarcinoma studies with a site in Washington, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic pancreatic adenocarcinoma study in Washington?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington to take part?
- Not necessarily. These studies have a site in Washington, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic pancreatic adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic pancreatic adenocarcinoma studies open in Washington regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.